505 Results

People

  1. Drilon
    Drilon
  2. Ladanyi
    Ladanyi
  3. Hyman
    Hyman
  4. Kris
    Kris
  5. Arcila
    Arcila
  6. Riely
    Riely
  7. Li
    Li
  8. Rudin
    Rudin
  9. Offin
    Offin
  10. Schram
    Schram

Groups

  1. Department of Medicine (505)
  2. Solid Tumor Oncology Division (505)
  3. Thoracic Oncology (505)
  4. GSK Faculty (159)
  5. Human Oncology and Pathogenesis Program (136)
  6. Tow Center for Developmental Oncology (TCDO) (114)
  7. Early Drug Development Service (102)
  8. Sloan Kettering Institute Postdocs (81)
  9. Epidemiology and Biostatistics (62)
  10. Radiology, Department of (60)
  1. "Thoracic Oncology"
  2. "Alexander Drilon"
Formats
  1. Meeting Abstract (297)
  2. Journal Article (180)
  3. Review (17)
  4. Editorial (5)
  5. Book Section (2)
  6. Book Whole (1)
  7. Correspondence (1)
  8. Guidelines (1)
  9. Research Letter (1)
Groups
  1. Department of Medicine (505)
  2. Solid Tumor Oncology Division (505)
  3. Thoracic Oncology (505)
  4. GSK Faculty (159)
  5. Human Oncology and Pathogenesis Program (136)
  6. Tow Center for Developmental Oncology (TCDO) (114)

More Groups

People
  1. Alexander Drilon (505)
  2. Marc Ladanyi (108)
  3. David Hyman (77)
  4. Mark Kris (75)
  5. Maria Arcila (72)
  6. Gregory Riely (58)

More People

Years
  1. 2023 (20)
  2. 2022 (85)
  3. 2021 (76)
  4. 2020 (80)
  5. 2019 (76)
  6. 2018 (55)

More Years

Publications
  1. Journal of Clinical Oncology (108)
  2. Annals of Oncology (72)
  3. Journal of Thoracic Oncology (65)
  4. Clinical Cancer Research (28)
  5. Cancer Research (23)
  6. Oncology Research and Treatment (20)

More Publications

Publishers
  1. American Society of Clinical Oncology (126)
  2. Elsevier Inc. (94)
  3. Oxford University Press (85)
  4. American Association for Cancer Research (67)
  5. Nature Publishing Group (24)
  6. S. Karger AG (20)

More Publishers

Results (505)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Quantifying the growth of clinical actionability in precision oncology using OncoKB
    Meeting Abstract

    Suehnholz, S. P.; Kundra, R.; Nandakumar, S.; Nissan, M. H.; Zhang, H.; Lu, C.; Dhaneshwar, A.; Fernandez, N.; Carrero, S.; Arcila, M. E.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • RET-altered cancers—A tumor-agnostic review of biology, diagnosis and targeted therapy activity
    Review

    Desilets, A.; Repetto, M.; Yang, S. R.; Sherman, E. J.; Drilon, A.
    Cancers (2023)

    Fulltext@MSK | Save
  • Combination therapy with MDM2 and MEK inhibitors is effective in patient-derived models of lung adenocarcinoma with concurrent oncogenic drivers and MDM2 amplification
    Journal Article

    Elkrief, A.; Odintsov, I.; Markov, V.; Caeser, R.; Sobczuk, P.; Tischfield, S. E.; Bhanot, U.; Vanderbilt, C. M.; Cheng, E. H.; Drilon, A.; more...
    Journal of Thoracic Oncology (2023)

    Fulltext@MSK | Save
  • SHP2 inhibition sensitizes diverse oncogene-addicted solid tumors to re-treatment with targeted therapy
    Journal Article

    Drilon, A.; Sharma, M. R.; Johnson, M. L.; Yap, T. A.; Gadgeel, S.; Nepert, D.; Feng, G.; Reddy, M. B.; Harney, A. S.; Elsayed, M.; more...
    Cancer Discovery (2023)

    Fulltext@MSK | Save
  • Mitogen-activated pathway kinase (MAPK) inhibitor-associated retinopathy: Do features differ with upstream versus down-stream inhibition?
    Journal Article

    Francis, J. H.; Foulsham, W.; Canestraro, J.; Harding, J. J.; Diamond, E. L.; Drilon, A.; Abramson, D. H.
    Ocular Oncology and Pathology (2023)

    Fulltext@MSK | Save
  • A demand-offer critical analysis of current drug development. Phase I drugs versus TCGA sequencing data
    Journal Article

    Repetto, M.; Crimini, E.; Belli, C.; Boscolo Bielo, L.; Ascione, L.; Meric-Bernstam, F.; Drilon, A.; Curigliano, G.
    European Journal of Cancer (2023)

    Fulltext@MSK | Save
  • NVL-655, a selective anaplastic lymphoma kinase (ALK) inhibitor, in patients with advanced ALK-positive solid tumors: The phase I/II ALKOVE-1 study
    Meeting Abstract

    Johnson, M. L.; Ou, S. H. I.; Felip, E.; Baik, C.; Besse, B.; Mazieres, J.; Camidge, D. R.; Gadgeel, S.; Drilon, A.; Elamin, Y. Y.; more...
    Journal of Thoracic Oncology (2023)

    Fulltext@MSK | Save
  • Trends in location of death for individuals with metastatic lung cancer in the United States
    Editorial

    Jain, U.; Jain, B.; Dee, E. C.; Bajaj, S. S.; Paguio, J. A.; Yao, J. S.; Gomez, D. R.; Celi, L. A.; Drilon, A.
    American Journal of Surgery (2023)

    Fulltext@MSK | Save
  • Case Report: Complete pathologic response to neoadjuvant selpercatinib in a patient with resectable early-stage RET fusion-positive non-small cell lung cancer
    Journal Article

    Goldman, J. W.; Sholl, L. M.; Dacic, S.; Fishbein, M. C.; Murciano-Goroff, Y. R.; Rajaram, R.; Szymczak, S.; Szpurka, A. M.; Chao, B. H.; Drilon, A.
    Frontiers in Oncology (2023)

    Fulltext@MSK | Save
  • Efficacy and ctDNA analysis in an updated cohort of patients with TRK fusion lung cancer treated with larotrectinib
    Meeting Abstract

    Hoejgaard, M.; Drilon, A.; Lin, J. J.; Kummar, S.; Tan, D. S. W.; Patel, J.; Leyvraz, S.; Garcia, V. Moreno; Rosen, L. S.; Solomon, B.; more...
    Journal of Thoracic Oncology (2023)

    Fulltext@MSK | Save